
==== Front
PLoS One
PLoS One
plos
PLOS ONE
1932-6203
Public Library of Science San Francisco, CA USA

10.1371/journal.pone.0308224
PONE-D-23-39743
Research Article
Biology and Life Sciences
Psychology
Developmental Psychology
Pervasive Developmental Disorders
Autism Spectrum Disorder
Autism
Social Sciences
Psychology
Developmental Psychology
Pervasive Developmental Disorders
Autism Spectrum Disorder
Autism
Medicine and Health Sciences
Medical Conditions
Neurodevelopmental Disorders
Autism
Biology and Life Sciences
Neuroscience
Developmental Neuroscience
Neurodevelopmental Disorders
Autism
Medicine and Health Sciences
Neurology
Neurodevelopmental Disorders
Autism
Biology and Life Sciences
Biochemistry
Metabolism
Metabolites
Biology and Life Sciences
Developmental Biology
Twins
Biology and Life Sciences
Biochemistry
Metabolism
Metabolic Pathways
Biology and Life Sciences
Anatomy
Body Fluids
Urine
Medicine and Health Sciences
Anatomy
Body Fluids
Urine
Biology and Life Sciences
Physiology
Body Fluids
Urine
Biology and Life Sciences
Biochemistry
Metabolism
Metabolomics
Research and Analysis Methods
Mathematical and Statistical Techniques
Statistical Methods
Multivariate Analysis
Principal Component Analysis
Physical Sciences
Mathematics
Statistics
Statistical Methods
Multivariate Analysis
Principal Component Analysis
Biology and Life Sciences
Biochemistry
Biomarkers
Urine metabolomic profiles of autism and autistic traits–A twin study
Urine metabolomic profiles of autism and autistic traits
https://orcid.org/0000-0002-6149-4417
Arora Abishek Conceptualization Data curation Formal analysis Funding acquisition Investigation Methodology Project administration Resources Software Validation Visualization Writing – original draft Writing – review & editing 1 2
https://orcid.org/0000-0003-4237-2446
Mastropasqua Francesca Methodology Writing – original draft Writing – review & editing 1 2
https://orcid.org/0000-0002-4579-4970
Bölte Sven Conceptualization Funding acquisition Investigation Project administration Resources Supervision Writing – review & editing 1 3 4
https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina Conceptualization Data curation Funding acquisition Investigation Methodology Project administration Resources Supervision Visualization Writing – original draft Writing – review & editing 1 2 *
1 Department of Women’s and Children’s Health, Center of Neurodevelopmental Disorders (KIND), Centre for Psychiatry Research, Karolinska Institutet, Stockholm, Sweden
2 Astrid Lindgren Children’s Hospital, Karolinska University Hospital, Region Stockholm, Stockholm, Sweden
3 Child and Adolescent Psychiatry, Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden
4 Curtin Autism Research Group, Curtin School of Allied Health, Curtin University, Perth, Western Australia
Brogna Claudia Editor
Fondazione Policlinico Universitario Gemelli IRCCS, ITALY
Competing Interests: A.A., F.M., and K.T. declare no competing interests. S.B. declares no direct conflict of interest related to this article. He discloses that he has in the last three years acted as an author, consultant, or lecturer for Medice and Roche. He receives royalties for textbooks and diagnostic tools from Hogrefe, Kohlhammer, UTB and Liber. S.B. is a partner in NeuroSupportSolutions International AB.

* E-mail: kristiina.tammimies@ki.se
3 9 2024
2024
19 9 e03082246 12 2023
19 7 2024
© 2024 Arora et al
2024
Arora et al
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Currently, there are no reliable biomarkers for autism diagnosis. The heterogeneity of autism and several co-occurring conditions are key challenges to establishing these. Here, we used untargeted mass spectrometry-based urine metabolomics to investigate metabolic differences for autism diagnosis and autistic traits in a well-characterized twin cohort (N = 105). We identified 208 metabolites in the urine samples of the twins. No clear, significant metabolic drivers for autism diagnosis were detected when controlling for other neurodevelopmental conditions. However, we identified nominally significant changes for several metabolites. For instance, phenylpyruvate (p = 0.019) and taurine (p = 0.032) were elevated in the autism group, while carnitine (p = 0.047) was reduced. We furthermore accounted for the shared factors, such as genetics within the twin pairs, and report additional metabolite differences. Based on the nominally significant metabolites for autism diagnosis, the arginine and proline metabolism pathway (p = 0.024) was enriched. We also investigated the association between quantitative autistic traits, as measured by the Social Responsiveness Scale 2nd Edition, and metabolite differences, identifying a greater number of nominally significant metabolites and pathways. A significant positive association between indole-3-acetate and autistic traits was observed within the twin pairs (adjusted p = 0.031). The utility of urine biomarkers in autism, therefore, remains unclear, with mixed findings from different study populations.

http://dx.doi.org/10.13039/501100004359 Vetenskapsrådet https://orcid.org/0000-0002-4579-4970
Bölte Sven http://dx.doi.org/10.13039/501100004359 Vetenskapsrådet https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina http://dx.doi.org/10.13039/501100001729 Stiftelsen för Strategisk Forskning https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina http://dx.doi.org/10.13039/501100003792 Hjärnfonden https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina http://dx.doi.org/10.13039/501100009759 Harald och Greta Jeanssons Stiftelse https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina http://dx.doi.org/10.13039/100007435 Åke Wiberg Stiftelse https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina Strategic Research Area Neuroscience Stratneuro https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina http://dx.doi.org/10.13039/501100001728 Swedish Foundation for International Cooperation in Research and Higher Education https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina http://dx.doi.org/10.13039/501100004047 Karolinska Institutet https://orcid.org/0000-0002-8324-4697
Tammimies Kristiina The project was supported by the Swedish Research Council (S.B., and K.T.), Swedish Foundation for Strategic Research (K.T.), the Swedish Brain Foundation – Hjärnfonden (K.T.), the Harald and Greta Jeanssons Foundations (K.T.), Åke Wiberg Foundation (K.T.), Strategic Research Area Neuroscience Stratneuro (K.T.), The Swedish Foundation for International Cooperation in Research and Higher Education STINT (K.T.), and Board of Research at Karolinska Institutet (K.T.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Data AvailabilityThe data is accessible, after necessary clearances, through the Swedish National Data Service’s (SND) research data catalogue and stored at the KI Data Repository (KI DR) (doi:available after acceptance). The utilised code is available on GitHub (https://github.com/Tammimies-Lab/RATSS-Metabolomics) or available upon request from the corresponding author."
Data Availability

The data is accessible, after necessary clearances, through the Swedish National Data Service’s (SND) research data catalogue and stored at the KI Data Repository (KI DR) (doi:available after acceptance). The utilised code is available on GitHub (https://github.com/Tammimies-Lab/RATSS-Metabolomics) or available upon request from the corresponding author."
==== Body
pmcIntroduction

Autism is a neurodevelopmental condition with a heterogeneous presentation that is diagnosed in 1 to 2% of the world population [1]. Although several genes and genetic variants have been associated with autism phenotypes [1–3], there is no evidence of a single biomarker that can be of benefit to the diagnostic procedure of the condition [4]. Finding biomarkers that could aid either in the diagnosis or specifying a subgroup of individuals could help, for instance, in the early diagnosis of autism [5].

Prior research has suggested an association of metabolic anomalies with autism that could potentially aid in the search for biomarkers [6]. Metabolomic analyses using urine samples provide a non-invasive method with greater ease of sample collection and handling in comparison to other biospecimens. This is particularly advantageous in clinical settings where the process of diagnosing autism can begin at a younger age [7]. Moreso, the ability to detect metabolites in urine samples is well-established using mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR), and the typical human urine metabolome has been mapped [8]. Early efforts to understand the urine metabolome in autism began several decades ago, with initial biochemical studies searching for associations [9, 10]. The investigations have shifted to more untargeted and high-precision analytical approaches using NMR [11, 12] and MS [13–15].

The interest in autism metabolomics has continued to expand; however, more accessible data are required across different populations to identify robust associations. Such an approach will also make it possible to characterise how both, situational and long-term environmental factors interplay with the genetic backgrounds of autism [16]. Twin studies are an appropriate tool to investigate the contribution of environmental and genetic factors [17, 18] and can be extended to metabolic profiles. It is especially valuable to analyse differences between monozygotic (MZ) twins who are discordant for autism, to tease out genetic contributions.

In this study, we utilised a rare twin sample, the Roots of Autism and ADHD Twin Study in Sweden (RATSS) [19, 20], enriched for MZ twins discordant for autism, and their urine sample-based metabolomics to search and validate potential metabolite biomarkers. Furthermore, on the basis of these findings we have mapped the affected metabolic pathways. Our study adds on to the literature exploring the metabolites as possible biomarkers for autism and expands the search for autistic traits.

Materials and methods

Study participants

In this study, individuals (N = 105) and 48 complete twin pairs were selected from the RATSS cohort [19, 20], which is a neurodevelopmental condition (NDC) enriched twin sample recruited from the general Swedish population between June 2011 and December 2015, for untargeted mass spectrometry-based urine metabolomics. Detailed inclusion and exclusion criteria for RATSS have been previously published [19]. Among the recruited twins, we selected participants for this study based on the autism diagnosis status, whether the twin pair was concordant (both with autism diagnosis) or discordant (only one with autism diagnosis) and if they had available urine samples. Furthermore, we age- and sex-matched the non-autistic twin pairs. The study was approved by the Swedish Ethical Review Authority (2016/1452-31). Written informed consent was obtained from all participants or their caregivers, based on their age.

During a 2.5-day study visit, a team of clinical professionals conducted a diagnostic evaluation of the participants in line with the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) guidelines [21]. The evaluation utilised a combination of diagnostic interviews, a review of medical history documents, and the use of established diagnostic measures [19]. This included behavioural assessment tools such as the Autism Diagnostic Interview-Revised (ADI-R) [22], the Autism Diagnostic Observation Schedule 2nd Edition (ADOS-2) [23]. Furthermore, additional tools were used to establish the diagnosis of other NDCs, if any, such the Diagnostic Interview for ADHD in Adults (DIVA-2) [24], the Structured Clinical Interview for DSM-IV (SCID-IV) [25], and the Adaptive Behavior Assessment System (ABAS) [26]–more detailed information about the same is available in the publication by Bölte and colleagues [19]. Autistic traits were evaluated with the parent-report version of the Social Responsiveness Scale 2nd Edition (SRS-2) [27–29], consisting of 65 items. Intelligence quotient (IQ) was measured by using the Wechsler Intelligence Scale for Children or Adults—IV General Ability Index (GAI) [30].

Additionally, the participants were asked for a list of their current, regularly used medications during the study visit. As there was a collection of different medications including antidepressants and ADHD medication, all were grouped together and adjusted for in our analyses. No subgrouping was possible for the drugs due to lack of power to detect metabolomic effects of specific drugs.

Urine collection and metabolite extraction

The urine samples were collected at the last day of the visit from the study participants. First, the participants were informed about the urine sample collection into a special urine cup. The urine cup was then given to a research nurse who transferred 10 mL of the collected urine to a sterile vacutainer tube with no additives. The sample was then directly transported, aliquoted and stored in the Karolinska Institutet Biobank at -80°C. The collected samples were further transported for analysis to the Proteomics and Metabolomics Facility, University of Tuscia, Italy. All samples were handled as per the same stated protocol. Before the metabolomic analysis, the urinary specific gravity was measured following centrifugation at 13,000 g for 10 minutes. Urine aliquots (200 μl) were mixed with 200 μl of methanol:acetonitrile:water (50:30:20), vortexed for 30 minutes, maximum speed at 4°C and then centrifuged at 16,000 g for 15 minutes at 4°C. Supernatants were collected for metabolomic analysis.

Ultra-High Performance Liquid Chromatography (UHPLC)

For the experiments, 20 μL of samples were injected into a UPLC system (Ultimate 3000, Thermo Scientific) and were analysed on positive mode: samples were loaded onto a Reprosil C18 column (2.0 mm × 150 mm, 2.5 μm—Dr Maisch, Germany) for metabolite separation. Chromatographic separations were achieved at a column temperature of 30°C and flow rate of 0.2 mL/min. A linear gradient (0–100%) of solvent A (ddH2O, 0.1% formic acid) to B (acetonitrile, 0.1% formic acid) was employed over 20 minutes, returning to 100% solvent A in 2 minutes and a 6-minute post-time solvent A hold. Acetonitrile, formic acid, and HPLC-grade water were purchased from Sigma Aldrich.

High Resolution Mass Spectrometry (HRMS)

The UPLC system was coupled online with a mass spectrometer, Q Exactive (Thermo Scientific), scanning in full MS mode (2 μ scans) at a resolution of 70,000 in the 67 to 1000 m/z range, target of 1 × 106 ions and a maximum ion injection time (IT) of 35 ms, 3.8 kV spray voltage, 40 sheath gas, and 25 auxiliary gas, operated in negative and then positive ion mode. Source ionization parameters were: spray voltage, 3.8 kV; capillary temperature, 300°C; and S-Lens level, 45. Calibration was performed before each analysis against positive or negative ion mode calibration mixes (Piercenet, Thermo Fisher, Rockford, IL) to ensure sub-ppm error of the intact mass.

Metabolite quantification

Data were normalized by urinary specific gravity because creatinine excretion may be abnormally reduced in autistic children [31]. Replicates were exported as mzXML files and processed through MAVEN [32]. Mass spectrometry chromatograms were elaborated for peak alignment, matching and comparison of parent and fragment ions, and tentative metabolite identification (within a 10-ppm mass deviation range between observed and expected results against the imported Kyoto Encyclopaedia of Genes and Genomes (KEGG) database [33].

Differential metabolomics

Principal component analysis (PCA) was performed in R [34] followed by visualisation with the factoextra package (https://cran.r-project.org/package=factoextra) to identify any outliers in the dataset. Prior to the PCA, missing values (0.018%) were imputed using the missMDA package [35] in R [34]. Here, the number of dimensions of the PCA were estimated by cross-validation using the k-fold method followed by imputation of missing values using the PCA model.

Differential metabolomic analysis for 208 metabolites was performed using the drgee package [36] in R [34], for overall effects and differences between twin pairs using a generalised estimating equations (GEE) model, with suitable covariates. For this analysis, missing values (0.018%) were not removed from the dataset and were treated as NA values. In the GEE model, the metabolites were individually considered as the response variable, while the autism diagnosis status was the predictor variable. Age, sex, body mass index (BMI), medication status and diagnosis status of other NDCs were added as covariates to the model: Metabolite ~ Autism Diagnosis + Other NDC Diagnosis + age + sex + BMI + medication status. The model was applied for the whole cohort (Model A) and for differences within twin pairs (Model B) through the drgee package [36] in R [34]. The same model was then applied to a subset of the cohort based on zygosity. Here, age and sex were removed as covariates when testing for differences between twin pairs as these were intrinsically controlled.

In addition to testing autism diagnosis status as a predictor variable, we used autistic traits measured by the SRS-2 [27–29] total raw scores. As IQ levels are known to have an impact on the SRS-2 scores [37], along with the previously stated covariates (other than diagnostic status of other NDCs), IQ scores from GAI were added to the models: Metabolite ~ SRS total raw score + age + sex + BMI + medication status + IQ GAI. Also, for SRS-2 total raw scores, the models were applied to subsets of the cohort based on zygosity. As previously stated, age and sex were removed as covariates when testing for differences between twin pairs as these were intrinsically controlled. For all instances, p values were extracted from the results of each model and adjusted for multiple comparisons using the false discovery rate (FDR) method [38] in R [34].

Pathway enrichment analysis

Significant metabolites from the GEE models were tested for enrichment in the Small Molecule Pathway Database (SMPDB) [39] using over-representation analysis (ORA) from the enrichment analysis module of MetaboAnalyst 5.0 [40]. The cut-off threshold for entries from metabolite sets to be included was set to 2. ORA was implemented using the hypergeometric test to evaluate whether a particular metabolite set is represented more than expected by chance within the given list of metabolites. One-tailed p values were provided after adjusting for multiple testing. Based on the statistical testing, enrichment dot-plots and pathway networks were generated. In the pathway networks, 2 or more nodes were only connected by an edge when the number of shared metabolites was >25% of the combined metabolites contributing to each node.

Statistical analysis and plots

All statistical analyses were performed in R (v4.1.2) [34]. The statistical models and tests used for the analyses are described in the methodology relevant to the experimental technique, in the sections above. All plots, unless otherwise stated, were created using the ggplot2 package (v3.3.5) [41] or the pheatmap package (v1.0.12, https://CRAN.R-project.org/package=pheatmap) in R (v4.1.2) [34].

Results

Metabolites do not clearly explain sample differences

UHPLC was coupled with HRMS for the untargeted analysis of metabolites. In the study cohort (N = 105 twins), of which 48 form complete twin pairs, we identified 208 metabolites with high reliability following mass spectrometry of urine samples. Principal component analysis (PCA) of the metabolomics data demonstrated no clear drivers of effects across PC1 (23.2%) and PC2 (10.8%) (Fig 1A). The first 10 principal components were able to explain 68.2% of the variation (Fig 1B). The loadings for PC1 (Fig 1C) and PC2 (Fig 1D) did not identify a metabolite that was a major driver of the observed effects, with the top 10 loadings having a contribution of ~1.25% to ~1.5% each in PC1 and ~1.75 to ~2.5% each in PC2. There were 9 individuals outside the 95% CI ellipses (Fig 1A), who were designated as outliers and excluded from further analysis, leaving a study cohort with 96 individuals, of which 42 form complete twin pairs. PCA was repeated on this subset of 96 samples to check if the prior removal of outliers better explained the variance of the dataset, however, this was to no avail. More outliers were therefore not removed based on further iterations of the PCA. Moreover, a lack of clear clusters following the PCA (Fig 1A) also ruled out the possibility of using the contemporarily favoured orthogonal partial least squares discriminant analysis (OPLS-DA) model for multivariate analysis in the full cohort [42].

10.1371/journal.pone.0308224.g001 Fig 1 Principal Component Analysis (PCA) of study cohort.

(A) Scatter plot for individuals based on metabolite contributions and grouped as per autism diagnosis status. (B) Scree plot of eigenvalues of principal components from A. (C) Loading plot of metabolites contributing to principal component 1 (PC1). (D) Loading plot of metabolites contributing to principal component 2 (PC2).

Of these 96 individuals selected for further analysis, the autistic participants had a mean age of 14 years, 11 being female and 24 having a clinical diagnosis of an NDC other than autism. The demographic and clinical features of the study cohort used for further analyses are summarised in Table 1. Specific information on race/ethnicity, socioeconomic status and educational attainment were not recorded.

10.1371/journal.pone.0308224.t001 Table 1 Demographic characteristics of study cohort.

Characteristics	Autism (n = 38)	Other (n = 58)	
Age, mean years (SD) [range]	14.21 (3.26) [8–21]	15.76 (3.14) [9–23]	
Sex, n females (%)	11 (29.95%)	22 (37.93%)	
MZ:DZ concordant pairs*	2:1	11:3	
Autism discordant pairs (n)*	14	
MZ	5	
DZ	9	
BMI, mean (SD) [range]	21 (5.41) [13–38]	21 (3.05) [15–30]	
Other NDC diagnosis n (%)	24 (63.16%)	8 (13.79%)	
Medication n (%)	24 (63.16%)	15 (23.86%)	
SRS-2, mean (SD) [range]	74 (18.66) [0–105]	48 (9.60) [35–78]	
IQ, mean (SD) [range]	86 (25.13) [0–138]	102 (13.81) [65–130]	
SD: Standard Deviation, MZ: Monozygotic, DZ: Dizygotic, BMI: Body Mass Index, NDC: Neurodevelopmental Condition, SRS-2: Social Responsiveness Scale 2nd Edition, IQ: Intelligence Quotient, * Complete twin pairs.

Subtle changes in metabolite status across study cohort

The peak areas of each identified metabolite from participants of the study cohort (N = 96) were analysed for association with autism diagnosis using a GEE model, first for the whole cohort (Model A) and then within twin pairs (Model B). We also adjusted the models for the diagnosis status of other NDCs. As expected, from the prior PCA, no metabolite had a significant association with autism after FDR correction for 208 tests. Based on nominal significance, a handful of metabolites were changed (S1A Table). For instance, deoxycholic acid (p = 0.048), orotate (p = 0.042), phenylpyruvate (p = 0.019) and taurine (p = 0.032) were elevated, while carnitine (p = 0.047) was reduced in autism (Fig 2A and S1A Table).

10.1371/journal.pone.0308224.g002 Fig 2 Heatmap of generalised estimating equations (GEE) model estimates.

(A) Autism diagnosis across full cohort (N = 96), monozygotic twins (n = 52) and dizygotic twins (n = 44) tested using GEE Models A and B. (B) Autistic traits across full cohort, monozygotic twins and dizygotic twins tested using GEE Models A and B. (* p<0.05, ** p<0.01, *** p<0.001).

When analysing for differences within twin pairs using the GEE model (Model B), i.e. which corrects for all the shared variation between the twins such as genetics and shared environment, eight metabolites were significantly modulated in the autism group based on the nominal p value (Fig 2A and S1A Table). These were increased hypoxanthine (p = 0.019), diiodothyronine (p = 0.049) and kynurenic acid (p = 0.003), and decreased guanidoacetic acid (p = 0.001), indole (p = 0.001) and L-arginosuccinate (p = 0.031).

The study cohort was then subsetted as per zygosity status and the same GEE models were applied for analysis. In the subset of MZ twins (n = 52), 17 metabolites were identified to be significantly different between autistic and other twins (Model A, Fig 2A and S1B Table), including an increase in unique metabolites such as alanine (p = 0.029), asparagine (p = 0.025) and 2-oxo-4-methylthiobutanoate (p = 0.007), and a decrease in creatine (p = 0.001) and deoxyinosine (p = 0.020). When testing for differences within the MZ twin pairs (Model B), 17 metabolites were differentially modulated (Fig 2A and S1B Table), including additional metabolites that were elevated like glutamine (p = 0.008), proline (p = 0.022) and homocysteine (p = 0.037). A decrease was detected in several metabolites, such as glucose-6-phosphate (p = 0.032), L-kynurenine (p = 0.043) and D-histidine (p = 0.014), among others.

In the subset for dizygotic (DZ) twins (n = 44), peak areas of only diidothyronine (p = 0.039) were elevated (Model A, Fig 2A and S1C Table). After accounting for differences within twin pairs in the GEE model (Model B), ten metabolites were significantly modulated (Fig 2A and S1C Table), such as an increase in valine (p = 0.018), quinoline (p = 0.034) and N-acetyl-glutamate (p = 0.046). Reductions were detected in four metabolites including isocitrate (p = 0.018) and indole (p = 0.009).

Association between autistic traits and metabolite differences

We also investigated associations between the metabolites and quantitative autistic traits measured by the SRS-2 total raw scores [27–29]. We analysed the association between the peak areas of each metabolite identified in the study cohort (N = 96) with the SRS-2 using the GEE models and adjusted for IQ (Wechsler GAI) [30]. Again, no metabolite reached statistical significance after FDR multiple test correction. From Model A, 30 nominally significant metabolites were detected (Fig 2B and S2A Table). Amongst those elevated were acetylcarnitine (p = 0.023), aspartate (p = 0.002) and hydroxyphenylpyruvate (p = 0.016); and the only metabolite to be reduced was creatine (p = 0.027). When testing for differences within the twin pairs (Model B), five metabolites crossed the nominal significance threshold (Fig 2B and S2A Table), including a decrease in adenosine (p = 0.025) and 6-phospho-d-gluconate (p = 0.033), and an increase in indole-3-acetate (p = 0.0001, adjusted p = 0.031).

We further explored the association in the zygosity groups for the autistic traits and the metabolites. In the MZ subset (n = 52), 12 metabolites demonstrated nominally significant changes when applying the GEE model (Model A, Fig 2B and S2B Table). An elevation was detected in coenzyme A (p = 0.044), AMP (p = 0.041) and a decline in levels of DL-pipecolic acid (p = 0.024). Following testing for differences within the twin pairs (Model B), six metabolites were identified (Fig 2B and S2B Table), which included an increase in prephenate (p = 0.027) and D-glycerylaldehyde 3-phosphate (p = 0.003) and a decrease in 5’-S-Methyl-5’-thioadenosine (p = 0.001) and thiamine (p = 0.032).

In the DZ subset (n = 44), 23 metabolites were significantly elevated (p<0.05) in association with the autistic traits (Model A, Fig 2B and S2C Table). These were, to name a few, D-methionine (p = 0.047), D-gluconate (p = 0.038), myo-inositol (p = 0.047) and lysine (p = 0.043). When accounting for differences between the twin pairs (Model B), 16 metabolites demonstrated significant changes (Fig 2B and S2C Table) where none were reduced, including glycolate (p = 0.009), 4-aminobutyrate (p = 0.035) and IMP (p = 0.012).

Enrichment of identified metabolites in biochemical pathways

The nominally significant metabolites identified from the GEE models were used for ORA as described in the methods. Ten biochemical pathways were identified to be enriched in the autistic twins based on the full cohort analysis (N = 96, Model A) (Fig 3A and 3B), out of which there was significant enrichment only in the bile acid biosynthesis pathway (p = 0.035, S3A Table). When ORA analysis was done for the metabolites found to be nominally significant for autism diagnosis between the twin pairs (Model B), ten pathways were identified (Fig 3C and 3D), where only the arginine and proline metabolism was significant (p = 0.024, S3B Table).

10.1371/journal.pone.0308224.g003 Fig 3 Pathway enrichment of significant metabolites based on autism diagnosis.

(A) Enrichment dot-plot for top 10 enriched pathways from GEE Model A. (B) Interaction network for enriched pathways from GEE Model A. (C) Enrichment dot-plot for top 10 enriched pathways from GEE Model B. (D) Interaction network for enriched pathways from GEE Model B.

For the models based on autistic traits in the full cohort (N = 96, Model A), 43 biochemical pathways were enriched (Fig 4B), out of which two crossed the significance threshold (S3C Table): glutathione metabolism (p = 0.0503) and glutamate metabolism (p = 0.0506). The enrichment dot-plot of the top ten pathways is depicted in Fig 4A. On the other hand, eight biochemical pathways were enriched from significant metabolites identified after testing for autistic traits between the twin pairs (Model B, S3D Table), of which methionine metabolism (p = 0.001) was significantly detected (Fig 4C and 4D).

10.1371/journal.pone.0308224.g004 Fig 4 Pathway enrichment of significant metabolites based on autistic traits.

(A) Enrichment dot-plot for top 10 enriched pathways from GEE Model A. (B) Interaction network for enriched pathways from GEE Model A. (C) Enrichment dot-plot for top 10 enriched pathways from GEE Model B. (D) Interaction network for enriched pathways from GEE Model B.

Discussion

In this study, we explored the urine metabolome of a subset of individuals from the RATSS cohort [19, 20] using untargeted mass-spectrometry. While only a single metabolite reached significance after FDR correction, we identified several metabolites as nominally significant for autism diagnosis and autistic traits. Furthermore, the identified metabolites were enriched in a few relevant biochemical pathways. Increased detection of significant metabolites was found for the autistic traits, rather than for the autism diagnoses.

Our study is the first to evaluate differences in the urine metabolome of an autism twin cohort and utilise information on co-occurring NDCs in our analyses. This is an important aspect to account for, when investigating suitable biomarkers in lieu of the high prevalence of co-occurring NDCs in autism [43]. The size of our study cohort (N = 96, with n = 38 diagnosed with autism) is larger when compared to several recently published studies using urine-based mass spectrometry, such as 60 available samples from an otherwise larger cohort [44], 57 participants [13] and 14 autism discordant sibling pairs [15]. The twin cohort also gives us the possibility to analyse the effects of genetic and environmental factors on these potential biomarkers. Despite this, we were not able to find any metabolites that reached the multiple test correction significance. However, a few were nominally associated similarly in the whole cohort and within twin pair analyses (Fig 2A). Our results show that the contribution of the shared factors, including genetics, in the metabolite profiles is strong and therefore it is difficult to find robust biomarkers of autism.

Our study is also the first to use autistic traits as measured by the SRS-2 as a predictor of metabolite changes. Predominantly, we found a large number of metabolites being associated with autistic traits rather than autism diagnosis. This shows potential that in the future, metabolite profiles could be used for detecting differences in continuous autism operationalisations. We observed a significant positive association between indole-3-acetate and autistic traits within the twin pairs. Elevated levels have been previously detected in autistic individuals [13, 45]. However, a decline has also been reported [46]. Indole-3-acetate is a known by-product of the tryptophan metabolism modulated by the gut microbiome [47, 48], with growing evidence indicating a dysbiosis [49, 50].

Despite the fact that we only found nominally associated metabolites, our findings align with previously reported urine-based metabolomic studies for autism diagnosis. For instance, we observed elevated levels of phenylpyruvate [14, 15] and taurine [11, 12, 51, 52], as noted earlier in several studies. We also show decreased levels of carnitine, similarly to what was reported in other biological samples [53, 54]. However, direct comparisons with metabolomic studies using different biological samples should be critically evaluated due to lack of information about any correlations between such reports, as observed in other multifactorial pathologies [55]. Our observations are unique when it comes to the association with autistic traits, as these have not been used as a predictor in metabolomic studies of autism before. While individual metabolites provide a snapshot into specific altered metabolic processes, interpretation of pathway level changes may be more relevant in multifactorial conditions like autism [56].

Several of the enriched pathways that were detected in this study are related to energy metabolism and mitochondrial function, which are crucial in the developing brain [57]. There are earlier studies that have linked such metabolic changes with autism physiology. These include the genetics [58] and functional differences [59] that contribute to atypical mitochondrial function in autism [60, 61]. We have also identified pathways related to amino acid metabolism, although with relatively lower confidence. This may nevertheless still prove to be an interesting aspect to investigate further, particularly with the recently growing evidence in this direction [62–64].

Even with a relatively larger cohort, our study like several others is limited by the size of the clinical cohort to identify robust and reproducible urine-based biomarkers of autism, if there are any. Despite, collecting the urine samples in the same manner for all study participants, variations in the sample handling could affect the metabolite profiles. Furthermore, since urine is an excretory by-product, dietary choices can influence the urine metabolome [65], both in neurotypical and autistic individuals. Future studies should aim to include this information in their analyses, accompanied with knowledge about the gut-microbiome status of study participants, as this can also be potentially associated with autism status [66]. It would also be essential to account for puberty related changes in the metabolism of adolescents while characterising the metabolome [67, 68]. Lastly, there is a need to replicate such studies in several international cohorts to test the value of identified biomarkers in different populations.

In conclusion, we have identified several urinary metabolites that show nominal association with autism diagnosis status and autistic traits. We have also determined the enrichment of the significant features in metabolic pathways. While our findings highlight no robust urine-based biomarkers for autism, this ever-increasing knowledgebase can serve as signposts for investigations in the future.

Supporting information

S1 Table GEE model for metabolites and autism diagnosis.

(A) Outcomes from modelling in full cohort. (B) Outcomes from modelling in monozygotic twins subsetted from full cohort. (C) Outcomes from modelling in dizygotic twins subsetted from full cohort.

(XLSX)

S2 Table GEE model for metabolites and autistic traits.

(A) Outcomes from modelling in full cohort. (B) Outcomes from modelling in monozygotic twins subsetted from full cohort. (C) Outcomes from modelling in dizygotic twins subsetted from full cohort.

(XLSX)

S3 Table Over representation analysis of significant metabolites.

(A) Enriched pathways from autism diagnosis and GEE Model A. (B) Enriched pathways from autism diagnosis and GEE Model B. (C) Enriched pathways from autistic traits and GEE Model A. (D) Enriched pathways from autistic traits and GEE Model B.

(XLSX)

We would like to thank all twins and parents who have participated in this research. We would also like to thank the RATSS team, especially Anna Pilfalk, Dr. Karl Lundin Remnelius, Dr. Johan Isaksson and Dr. Janina Neufeld for their valuable contribution to the work presented in this study. Additionally, we would like thank Prof. Antonio Persico for early discussion on designing the project. We acknowledge the Swedish Twin Registry for data access and urine analysis by the Proteomics and Metabolomics Facility, Department of Ecological and Biological Sciences, University of Tuscia, Viterbo, Italy and Prof. Lello Zolla.

10.1371/journal.pone.0308224.r001
Decision Letter 0
Brogna Claudia Academic Editor
© 2024 Claudia Brogna
2024
Claudia Brogna
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version0
15 Apr 2024

PONE-D-23-39743Urine metabolomic profiles of autism and autistic traits – a twin studyPLOS ONE

Dear Dr. Tammimies,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by May 30 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Claudia Brogna

Academic Editor

PLOS ONE

Journal requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match. 

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

3. Thank you for stating the following financial disclosure: "The project was supported by the Swedish Research Council (S.B., and K.T.), Swedish

Foundation for Strategic Research (K.T.), the Swedish Brain Foundation – Hjärnfonden (K.T.), the Harald and Greta Jeanssons Foundations (K.T.), Åke Wiberg Foundation (K.T.), Strategic Research Area Neuroscience Stratneuro (K.T.), The Swedish Foundation for International Cooperation in Research and Higher Education STINT (K.T.), and Board of Research at Karolinska Institutet (K.T.). " 

Please state what role the funders took in the study.  If the funders had no role, please state: ""The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."" 

If this statement is not correct you must amend it as needed. 

Please include this amended Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

4. In the online submission form, you indicated that the mass spectrometry data is accessible from the corresponding author after necessary

clearances. The utilised code is available on GitHub (https://github.com/Tammimies-

Lab/RATSS-Metabolomics) or available upon request from the corresponding author.. 

All PLOS journals now require all data underlying the findings described in their manuscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption request will be escalated for approval. 

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section. 

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. 

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Autism disorders were well-recognized as a metabolic disease in the past decades. Urinary biomarkers are very useful to identify this spectrum. So it needs more broad consideration to get the conclusion with negative results.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Attachment Submitted filename: review PONE.docx

10.1371/journal.pone.0308224.r002
Author response to Decision Letter 0
Submission Version1
6 Jun 2024

Reviewer

The metabolomic analysis in twin-cohort to discover urinary biomarker of autism is interesting and of significance. It is valuable to tease out many confounding factors, as gene and environment factors. Although no significant metabolic drivers for autism diagnosis were detected when controlling for other neurodevelopmental conditions. Some nominally changes were found within the twin pairs.

Nevertheless, we have the following questions：

1. For PCA analysis, 9 individuals were outliers and excluded, but no better clustering and explained in further repeated PCA. What is the conceptual basis and meaning for excluding individual?

As rightly stated, following PCA, 9 individuals were designated as outliers and excluded as they were outside the 95% confidence interval ellipses of the scatter plot for the most explanato-ry principal components (PC1 and PC2, Figure 1A). Further repeated PCAs did not improve clustering and were therefore not included. This rationale and our approach to handling outliers in this study is stated in the manuscript (lines 208 – 213). The removal of the outliers was done based on recommendations in the field (PMID: 38179935). Nevertheless, only 8.57% of the total study participants (N=105) were excluded, which would not have a statistical impact on our findings.

2. For untargeted metabolomics, features identified by the UPLC-MS should be listed and offer more details, as m/z, rt or fragmentation similarity, etc. It is important for ex-hibiting confidence in annotating metabolites.

The 208 features identified following untargeted metabolomic using UHPLC-MS have been stated in Table S1 and Table S2. The UHPLC-MS analysis and annotation were performed by the Proteomics and Metabolomics Facility of the University of Tuscia, Italy, using their stand-ard established pipeline (lines 114 – 148). This analytical approach has also been utilised in previously published papers (PMIDs 32512190 and 27904735) by members of the core facili-ty. Unfortunately, we were not able to get the m/z, rt or fragmentation similarity from the core facility but only the standard annotated metabolites as reported. As the metabolomics analysis was performed on a clinical cohort, further data cannot be included in this manuscript in lieu of ethical considerations.

3. Urine is an unstable milieu, collection time and method may affect the results. While no information was given in the manuscript. Please explain your consideration of these factors.

Thank you for noting, we have now included more information about how the urine was col-lected from the participants (lines 110 – 116). We additionally added a sentence about the col-lection of the urine samples and instability to the manuscript’s discussion (lines: 381 – 382).

4. As mentioned in the manuscript, indole-3-acetate is positive associated with autistic traits within the twin pairs. If it is possible to assess the potential of indole-3-acetate as a predictor?

Although, indole-3-acetate is positively associated with autistic traits within the twin-pairs, it would not be appropriate to access its potential role as a predictor due to the confounding ef-fects of participant genetics.

Academic Editor

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

The manuscript has been updated to meet the shared style requirements of PLOS ONE, includ-ing the naming of all uploaded files.

2. We note that the grant information you provided in the ‘Funding Information’ and ‘Financial Disclosure’ sections do not match.

When you resubmit, please ensure that you provide the correct grant numbers for the awards you received for your study in the ‘Funding Information’ section.

We have ensured that the grant information provided at the time of resubmission matches that which is included in the manuscript (lines 415 – 422).

3. Thank you for stating the following financial disclosure: "The project was supported by the Swedish Research Council (S.B., and K.T.), Swedish Foundation for Strategic Research (K.T.), the Swedish Brain Foundation – Hjärnfonden (K.T.), the Harald and Greta Jeanssons Foundations (K.T.), Åke Wiberg Foundation (K.T.), Strategic Research Area Neuroscience Stratneuro (K.T.), The Swedish Foundation for International Coop-eration in Research and Higher Education STINT (K.T.), and Board of Research at Ka-rolinska Institutet (K.T.). " Please state what role the funders took in the study. If the funders had no role, please state: ""The funders had no role in study design, data col-lection and analysis, decision to publish, or preparation of the manuscript."

If this statement is not correct you must amend it as needed. Please include this amend-ed Role of Funder statement in your cover letter; we will change the online submission form on your behalf.

The funders had no role in this study and this has been stated in the funding information (lines 420 – 422), as shared in the above-mentioned statement.

4. In the online submission form, you indicated that the mass spectrometry data is ac-cessible from the corresponding author after necessary clearances. The utilised code is available on GitHub (https://github.com/Tammimies-Lab/RATSS-Metabolomics) or available upon request from the corresponding author.

All PLOS journals now require all data underlying the findings described in their man-uscript to be freely available to other researchers, either 1. In a public repository, 2. Within the manuscript itself, or 3. Uploaded as supplementary information.

This policy applies to all data except where public deposition would breach compliance with the protocol approved by your research ethics board. If your data cannot be made publicly available for ethical or legal reasons (e.g., public availability would compromise patient privacy), please explain your reasons on resubmission and your exemption re-quest will be escalated for approval.

The data included in this manuscript pertains to clinical research and cannot be made publicly available for ethical and legal reasons as this would compromise patient privacy.

5. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please delete it from any other section.

The ethics statement is included in the Materials and methods section (lines 86 – 88) and has been removed from any other section of the manuscript.

6. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Sup-porting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information.

Captions for the Supporting information files have been included in the manuscript (lines 437 – 448) and match the in-text citations.

Attachment Submitted filename: RATSS_Reviewer_Comments_Response.pdf

10.1371/journal.pone.0308224.r003
Decision Letter 1
Brogna Claudia Academic Editor
© 2024 Claudia Brogna
2024
Claudia Brogna
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Submission Version1
19 Jul 2024

Urine metabolomic profiles of autism and autistic traits – a twin study

PONE-D-23-39743R1

Dear Dr.Kristiina Tammimies,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Claudia Brogna

Academic Editor

PLOS ONE

10.1371/journal.pone.0308224.r004
Acceptance letter
Brogna Claudia Academic Editor
© 2024 Claudia Brogna
2024
Claudia Brogna
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
24 Jul 2024

PONE-D-23-39743R1

PLOS ONE

Dear Dr. Tammimies,

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team.

At this stage, our production department will prepare your paper for publication. This includes ensuring the following:

* All references, tables, and figures are properly cited

* All relevant supporting information is included in the manuscript submission,

* There are no issues that prevent the paper from being properly typeset

If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps.

Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

If we can help with anything else, please email us at customercare@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Claudia Brogna

Academic Editor

PLOS ONE
==== Refs
References

1 Lord C , Brugha TS , Charman T , Cusack J , Dumas G , Frazier T , et al . Autism spectrum disorder. Nat Rev Dis Primer. 2020;6 : 5. doi: 10.1038/s41572-019-0138-4 31949163
2 Satterstrom FK , Kosmicki JA , Wang J , Breen MS , De Rubeis S , An J-Y , et al . Large-Scale Exome Sequencing Study Implicates Both Developmental and Functional Changes in the Neurobiology of Autism. Cell. 2020; S0092867419313984. doi: 10.1016/j.cell.2019.12.036 31981491
3 Zhou X , Feliciano P , Shu C , Wang T , Astrovskaya I , Hall JB , et al . Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes. Nat Genet. 2022;54 : 1305–1319. doi: 10.1038/s41588-022-01148-2 35982159
4 Cortese S , Solmi M , Michelini G , Bellato A , Blanner C , Canozzi A , et al . Candidate diagnostic biomarkers for neurodevelopmental disorders in children and adolescents: a systematic review. World Psychiatry. 2023;22 : 129–149. doi: 10.1002/wps.21037 36640395
5 Amaral DG , Anderson GM , Bailey A , Bernier R , Bishop S , Blatt G , et al . Gaps in current autism research: The thoughts of the Autism Research Editorial Board and Associate Editors. Autism Res. 2019. doi: 10.1002/aur.2101 31025542
6 Jensen AR , Lane AL , Werner BA , McLees SE , Fletcher TS , Frye RE . Modern Biomarkers for Autism Spectrum Disorder: Future Directions. Mol Diagn Ther. 2022;26 : 483–495. doi: 10.1007/s40291-022-00600-7 35759118
7 Lord C. Recognising the heterogeneity of autism. Lancet Psychiatry. 2019;6 : 551–552. doi: 10.1016/S2215-0366(19)30220-2 31230673
8 Bouatra S , Aziat F , Mandal R , Guo AC , Wilson MR , Knox C , et al . The Human Urine Metabolome. Dzeja P , editor. PLoS ONE. 2013;8 : e73076. doi: 10.1371/journal.pone.0073076 24023812
9 Himwich HE , Jenkins RL , Fujimori M , Narasimhachari N , Ebersole M . A biochemical study of early infantile autism. J Autism Child Schizophr. 1972;2 : 114–126. doi: 10.1007/BF01537565 5068665
10 Young JG , Cohen DJ , Brown SL , Caparulo BK . Decreased urinary free catecholamines in childhood autism. J Am Acad Child Psychiatry. 1978;17 : 671–678. doi: 10.1016/s0002-7138(09)61019-0 744850
11 Ma Y , Zhou H , Li C , Zou X , Luo X , Wu L , et al . Differential Metabolites in Chinese Autistic Children: A Multi-Center Study Based on Urinary 1H-NMR Metabolomics Analysis. Front Psychiatry. 2021;12 : 624767. doi: 10.3389/fpsyt.2021.624767 34045978
12 Mavel S , Nadal-Desbarats L , Blasco H , Bonnet-Brilhault F , Barthélémy C , Montigny F , et al . 1H–13C NMR-based urine metabolic profiling in autism spectrum disorders. Talanta. 2013;114 : 95–102. doi: 10.1016/j.talanta.2013.03.064 23953447
13 Mussap M , Siracusano M , Noto A , Fattuoni C , Riccioni A , Rajula HSR , et al . The Urine Metabolome of Young Autistic Children Correlates with Their Clinical Profile Severity. Metabolites. 2020;10 : 476. doi: 10.3390/metabo10110476 33238400
14 Noto A , Fanos V , Barberini L , Grapov D , Fattuoni C , Zaffanello M , et al . The urinary metabolomics profile of an Italian autistic children population and their unaffected siblings. J Matern Fetal Neonatal Med. 2014;27 : 46–52. doi: 10.3109/14767058.2014.954784 25284177
15 Timperio AM , Gevi F , Cucinotta F , Ricciardello A , Turriziani L , Scattoni ML , et al . Urinary Untargeted Metabolic Profile Differentiates Children with Autism from Their Unaffected Siblings. Metabolites. 2022;12 : 797. doi: 10.3390/metabo12090797 36144201
16 Bai D , Yip BHK , Windham GC , Sourander A , Francis R , Yoffe R , et al . Association of Genetic and Environmental Factors With Autism in a 5- Country Cohort. JAMA Psychiatry. 2019;76 : 1035. doi: 10.1001/jamapsychiatry.2019.1411 31314057
17 Colvert E , Tick B , McEwen F , Stewart C , Curran SR , Woodhouse E , et al . Heritability of Autism Spectrum Disorder in a UK Population-Based Twin Sample. JAMA Psychiatry. 2015;72 : 415. doi: 10.1001/jamapsychiatry.2014.3028 25738232
18 Frazier TW , Thompson L , Youngstrom EA , Law P , Hardan AY , Eng C , et al . A Twin Study of Heritable and Shared Environmental Contributions to Autism. J Autism Dev Disord. 2014;44 : 2013–2025. doi: 10.1007/s10803-014-2081-2 24604525
19 Bölte S , Willfors C , Berggren S , Norberg J , Poltrago L , Mevel K , et al . The Roots of Autism and ADHD Twin Study in Sweden (RATSS). Twin Res Hum Genet. 2014;17 : 164–176. doi: 10.1017/thg.2014.12 24735654
20 Myers L , Pan P , Remnélius KL , Neufeld J , Marschik PB , Jonsson U , et al . Behavioral and biological divergence in monozygotic twin pairs discordant for autism phenotypes: A systematic review. JCPP Adv. 2021;1 . doi: 10.1111/jcv2.12017 37431470
21 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. American Psychiatric Association; 2013. doi: 10.1176/appi.books.9780890425596
22 Rutter M , Le Couteur A , Lord C . Autism diagnostic interview-revised. Los Angel CA West Psychol Serv. 2003;29 : 30.
23 Lord C , Rutter M , DiLavore P , Risi S , Gotham K , Bishop S . Autism diagnostic observation schedule–2nd edition (ADOS-2). Los Angel CA West Psychol Corp. 2012;284.
24 Kooij J , Francken M . Diagnostic interview for ADHD in adults 2.0 (DIVA 2.0). Adult ADHD Diagn Assess Treat. 2010; 33–99.
25 First MB , Gibbon M . The structured clinical interview for DSM-IV axis I disorders (SCID-I) and the structured clinical interview for DSM-IV axis II disorders (SCID-II). 2004.
26 Harrison PL , Oakland T . Adaptive behavior assessment system. Psychological Corporation San Antonio, TX; 2000.
27 Constantino JN . Social Responsivness Scale (SRS). Western Psychological Services.; 2005.
28 Constantino JN . The Quantitative Nature of Autistic Social Impairment: Pediatr Res. 2011;69 : 55R–62R. doi: 10.1203/PDR.0b013e318212ec6e 21289537
29 Constantino JN , Gruber CP . Skattningsskala för social responsivitet, andra upplagan (SRS-2) [Social Responsiveness Scale, Second Edition (SRS-2)] [Swedish version by Zander E. & Bölte S. ]. Hogrefe; 2012.
30 Tulsky DS , Saklofske DH , Wilkins C , Weiss LG . Development of a General Ability Index for the Wechsler Adult Intelligence Scale—Third Edition. Psychol Assess. 2001;13 : 566–571. doi: 10.1037//1040-3590.13.4.566 11793899
31 Whiteley P , Waring R , Williams L , Klovrza L , Nolan F , Smith S , et al . Spot urinary creatinine excretion in pervasive developmental disorders. Pediatr Int. 2006;48 : 292–297. doi: 10.1111/j.1442-200X.2006.02207.x 16732798
32 Melamud E , Vastag L , Rabinowitz JD . Metabolomic Analysis and Visualization Engine for LC−MS Data. Anal Chem. 2010;82 : 9818–9826. doi: 10.1021/ac1021166 21049934
33 Kanehisa M , Furumichi M , Sato Y , Kawashima M , Ishiguro-Watanabe M . KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 2023;51 : D587–D592. doi: 10.1093/nar/gkac963 36300620
34 R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.; 2020. Available: https://www.R-project.org/.
35 Josse J , Husson F . missMDA: A Package for Handling Missing Values in Multivariate Data Analysis. J Stat Softw. 2016;70 . doi: 10.18637/jss.v070.i01
36 Zetterqvist J , Sjölander A . Doubly Robust Estimation with the R Package drgee. Epidemiol Methods. 2015;4 . doi: 10.1515/em-2014-0021
37 Hirosawa T , Kontani K , Fukai M , Kameya M , Soma D , Hino S , et al . Different associations between intelligence and social cognition in children with and without autism spectrum disorders. Richey J , editor. PLOS ONE. 2020;15 : e0235380. doi: 10.1371/journal.pone.0235380 32822358
38 Benjamini Y , Hochberg Y . Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. J R Stat Soc Ser B Methodol. 1995;57 : 289–300. doi: 10.1111/j.2517-6161.1995.tb02031.x
39 Jewison T , Su Y , Disfany FM , Liang Y , Knox C , Maciejewski A , et al . SMPDB 2.0: Big Improvements to the Small Molecule Pathway Database. Nucleic Acids Res. 2014;42 : D478–D484. doi: 10.1093/nar/gkt1067 24203708
40 Pang Z , Zhou G , Ewald J , Chang L , Hacariz O , Basu N , et al . Using MetaboAnalyst 5.0 for LC–HRMS spectra processing, multi-omics integration and covariate adjustment of global metabolomics data. Nat Protoc. 2022;17 : 1735–1761. doi: 10.1038/s41596-022-00710-w 35715522
41 Wickham H. ggplot2. New York, NY: Springer New York; 2009. doi: 10.1007/978-0-387-98141-3
42 Worley B , Powers R . PCA as a Practical Indicator of OPLS-DA Model Reliability. Curr Metabolomics. 2016;4 : 97–103. doi: 10.2174/2213235X04666160613122429 27547730
43 Khachadourian V , Mahjani B , Sandin S , Kolevzon A , Buxbaum JD , Reichenberg A , et al . Comorbidities in autism spectrum disorder and their etiologies. Transl Psychiatry. 2023;13 : 71. doi: 10.1038/s41398-023-02374-w 36841830
44 Liu W , Li L , Xia X , Zhou X , Du Y , Yin Z , et al . Integration of Urine Proteomic and Metabolomic Profiling Reveals Novel Insights Into Neuroinflammation in Autism Spectrum Disorder. Front Psychiatry. 2022;13 : 780747. doi: 10.3389/fpsyt.2022.780747 35615451
45 Gevi F , Zolla L , Gabriele S , Persico AM . Urinary metabolomics of young Italian autistic children supports abnormal tryptophan and purine metabolism. Mol Autism. 2016;7 : 47. doi: 10.1186/s13229-016-0109-5 27904735
46 Emond P , Mavel S , Aïdoud N , Nadal-Desbarats L , Montigny F , Bonnet-Brilhault F , et al . GC-MS-based urine metabolic profiling of autism spectrum disorders. Anal Bioanal Chem. 2013;405 : 5291–5300. doi: 10.1007/s00216-013-6934-x 23571465
47 Krishnan S , Ding Y , Saedi N , Choi M , Sridharan GV , Sherr DH , et al . Gut Microbiota-Derived Tryptophan Metabolites Modulate Inflammatory Response in Hepatocytes and Macrophages. Cell Rep. 2018;23 : 1099–1111. doi: 10.1016/j.celrep.2018.03.109 29694888
48 Pavlova T , Vidova V , Bienertova-Vasku J , Janku P , Almasi M , Klanova J , et al . Urinary intermediates of tryptophan as indicators of the gut microbial metabolism. Anal Chim Acta. 2017;987 : 72–80. doi: 10.1016/j.aca.2017.08.022 28916042
49 Kang D-W , Park JG , Ilhan ZE , Wallstrom G , LaBaer J , Adams JB , et al . Reduced Incidence of Prevotella and Other Fermenters in Intestinal Microflora of Autistic Children. Gilbert JA , editor. PLoS ONE. 2013;8 : e68322. doi: 10.1371/journal.pone.0068322 23844187
50 Wan Y , Zuo T , Xu Z , Zhang F , Zhan H , Chan D , et al . Underdevelopment of the gut microbiota and bacteria species as non-invasive markers of prediction in children with autism spectrum disorder. Gut. 2022;71 : 910–918. doi: 10.1136/gutjnl-2020-324015 34312160
51 Nadal-Desbarats L , Aïdoud N , Emond P , Blasco H , Filipiak I , Sarda P , et al . Combined 1 H-NMR and 1 H– 13 C HSQC-NMR to improve urinary screening in autism spectrum disorders. The Analyst. 2014;139 : 3460–3468. doi: 10.1039/C4AN00552J 24841505
52 Yap IKS , Angley M , Veselkov KA , Holmes E , Lindon JC , Nicholson JK . Urinary Metabolic Phenotyping Differentiates Children with Autism from Their Unaffected Siblings and Age-Matched Controls. J Proteome Res. 2010;9 : 2996–3004. doi: 10.1021/pr901188e 20337404
53 Fahmy SF , El-hamamsy MH , Zaki OK , Badary OA . l-Carnitine supplementation improves the behavioral symptoms in autistic children. Res Autism Spectr Disord. 2013;7 : 159–166. doi: 10.1016/j.rasd.2012.07.006
54 Filipek PA , Juranek J , Nguyen MT , Cummings C , Gargus JJ . Relative Carnitine Deficiency in Autism. J Autism Dev Disord. 2004;34 : 615–623. doi: 10.1007/s10803-004-5283-1 15679182
55 Erben V , Poschet G , Schrotz-King P , Brenner H . Comparing Metabolomics Profiles in Various Types of Liquid Biopsies among Screening Participants with and without Advanced Colorectal Neoplasms. Diagnostics. 2021;11 : 561. doi: 10.3390/diagnostics11030561 33804777
56 Arora A , Becker M , Marques C , Oksanen M , Li D , Mastropasqua F , et al . Screening autism-associated environmental factors in differentiating human neural progenitors with fractional factorial design-based transcriptomics. Sci Rep. 2023;13 : 10519. doi: 10.1038/s41598-023-37488-0 37386098
57 Bülow P , Patgiri A , Faundez V . Mitochondrial protein synthesis and the bioenergetic cost of neurodevelopment. iScience. 2022;25 : 104920. doi: 10.1016/j.isci.2022.104920 36060058
58 Varga NÁ , Pentelényi K , Balicza P , Gézsi A , Reményi V , Hársfalvi V , et al . Mitochondrial dysfunction and autism: comprehensive genetic analyses of children with autism and mtDNA deletion. Behav Brain Funct. 2018;14 : 4. doi: 10.1186/s12993-018-0135-x 29458409
59 Giulivi C , Zhang Y-F , Omanska-Klusek A , Ross-Inta C , Wong S , Hertz-Picciotto I , et al . Mitochondrial Dysfunction in Autism. JAMA. 2010. doi: 10.1001/jama.2010.1706 21119085
60 Frye RE . Mitochondrial Dysfunction in Autism Spectrum Disorder: Unique Abnormalities and Targeted Treatments. Semin Pediatr Neurol. 2020;35 : 100829. doi: 10.1016/j.spen.2020.100829 32892956
61 Rossignol DA , Frye RE . Mitochondrial dysfunction in autism spectrum disorders: a systematic review and meta-analysis. Mol Psychiatry. 2012;17 : 290–314. doi: 10.1038/mp.2010.136 21263444
62 Chen W-X , Liu B , Zhou L , Xiong X , Fu J , Huang Z-F , et al . De novo mutations within metabolism networks of amino acid/protein/energy in Chinese autistic children with intellectual disability. Hum Genomics. 2022;16 : 52. doi: 10.1186/s40246-022-00427-7 36320054
63 Tărlungeanu DC , Deliu E , Dotter CP , Kara M , Janiesch PC , Scalise M , et al . Impaired Amino Acid Transport at the Blood Brain Barrier Is a Cause of Autism Spectrum Disorder. Cell. 2016;167 : 1481–1494.e18. doi: 10.1016/j.cell.2016.11.013 27912058
64 Zhu J , Hua X , Yang T , Guo M , Li Q , Xiao L , et al . Alterations in Gut Vitamin and Amino Acid Metabolism are Associated with Symptoms and Neurodevelopment in Children with Autism Spectrum Disorder. J Autism Dev Disord. 2022;52 : 3116–3128. doi: 10.1007/s10803-021-05066-w 34263410
65 Stratakis N , Siskos AP , Papadopoulou E , Nguyen AN , Zhao Y , Margetaki K , et al . Urinary metabolic biomarkers of diet quality in European children are associated with metabolic health. eLife. 2022;11 : e71332. doi: 10.7554/eLife.71332 35076016
66 Taniya MA , Chung H-J , Al Mamun A , Alam S , Aziz MdA , Emon NU , et al . Role of Gut Microbiome in Autism Spectrum Disorder and Its Therapeutic Regulation. Front Cell Infect Microbiol. 2022;12 : 915701. doi: 10.3389/fcimb.2022.915701 35937689
67 Cominetti O , Hosking J , Jeffery A , Pinkney J , Martin F-P . Contributions of Fat and Carbohydrate Metabolism to Glucose Homeostasis in Childhood Change With Age and Puberty: A 12-Years Cohort Study (EARLYBIRD 77). Front Nutr. 2020;7 : 139. doi: 10.3389/fnut.2020.00139 32984398
68 Perng W , Rifas-Shiman SL , Hivert M-F , Chavarro JE , Sordillo J , Oken E . Metabolic trajectories across early adolescence: differences by sex, weight, pubertal status and race/ethnicity. Ann Hum Biol. 2019;46 : 205–214. doi: 10.1080/03014460.2019.1638967 31264447
